NovelMed is a privately-held biotechnology company developing second generation therapies for orphan and non-orphan diseases with a specific focus on blocking certain parts of the immune system involved in the disease process. With our unique portfolio of neutralizing monoclonal antibodies, NovelMed is targeting acute and chronic diseases with large market potential and unmet medical need.
Our portfolio of therapeutic antibodies has been selected through rigorous testing using in vitro, ex vivo and in vivo assays. We specialize in antibody-based therapeutics as well as targeted small molecule drugs. Over the last decade, we have generated pre-clinical data and accumulated significant intellectual property to cover the discovery and development of our lead products. Efficacy studies in key animal models have enabled identification of several leading drug candidates for acute and chronic clinical indications.
NovelMed is currently seeking pharma/venture partners to develop its portfolio of unique therapies for orphan & non-orphan indications. Learn more . . .